Xbrane Biopharma AB (publ) (STO:XBRANE)

Market Cap	267.87M +23.5%
Revenue (ttm)	127.95M -38.8%
Net Income	-62.68M
EPS	-3.04
Shares Out	20.61M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	249,216
Open	14.15
Previous Close	14.15
Day's Range	12.25 - 14.15
52-Week Range	5.42 - 20.00
Beta	0.73
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2026

About Xbrane Biopharma AB

Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. The company also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 29
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: XBRANE

Financial Performance

Data Sources: S&P Global Market Intelligence and QUODD

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by QUODD.

Last checked:

Nov 2, 2026

Data Sources Report a data error